Abeona (NASDAQ: ABEO) CFO sells 785 shares to cover tax obligations

Rhea-AI Filing Summary

Abeona Therapeutics Inc.’s Chief Financial Officer Joseph Walter Vazzano reported an open-market sale of 785 shares of common stock. The shares were sold at $4.76 each on the transaction date to cover tax obligations associated with the vesting of restricted stock awards. After this transaction, he directly holds 567,775 shares of Abeona common stock.

Insider Trade Summary

Net Seller: 785 shares ($3,737)

Net Sell 1 txn

Insider Vazzano Joseph Walter

Role Chief Financial Officer

Sold 785 shs ($4K)

Type	Security	Shares	Price	Value
Sale	Common Stock	785	$4.76	$4K

Holdings After Transaction: Common Stock — 567,775 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vazzano Joseph Walter

(Last) (First) (Middle)

6555 CARNEGIE AVE., 4TH FLOOR

(Street)

CLEVELAND OH 44103

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ABEONA THERAPEUTICS INC. [ ABEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/16/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/16/2026		S(1)		785	D	$4.76	567,775	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards.

	/s/ Joseph Vazzano	03/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Abeona Therapeutics (ABEO) report in this Form 4?

Abeona Therapeutics reported that CFO Joseph Walter Vazzano sold 785 shares of common stock at $4.76 per share. The filing notes this sale was specifically made to cover tax obligations from vesting restricted stock awards, a common administrative transaction for equity compensation.

Who is the insider involved in the latest ABEO Form 4 filing?

The insider is Joseph Walter Vazzano, Chief Financial Officer of Abeona Therapeutics. He executed an open-market sale of 785 common shares at $4.76 each, with the filing stating the sale covered tax obligations tied to restricted stock award vesting.

How many Abeona Therapeutics (ABEO) shares did the CFO sell and at what price?

The CFO sold 785 shares of Abeona Therapeutics common stock at a price of $4.76 per share. This sale, reported as an open-market transaction, was described in the filing as being used to satisfy tax obligations from vesting restricted stock awards.

How many ABEO shares does the CFO hold after the reported Form 4 transaction?

Following the sale, the CFO directly holds 567,775 shares of Abeona Therapeutics common stock. This post-transaction holding figure comes directly from the Form 4 and shows his remaining equity position after selling 785 shares to cover tax obligations.

Why did the Abeona Therapeutics (ABEO) CFO sell shares in this Form 4?

The filing states the sale was conducted to cover tax obligations associated with the vesting of restricted stock awards. Such transactions are typically administrative, ensuring required taxes are paid when equity compensation vests, rather than indicating a strategic portfolio shift.